Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue: 2024-2025
Historic Non-Current Deffered Revenue for Aclaris Therapeutics (ACRS) over the last 1 years, with Sep 2025 value amounting to $17.5 million.
- Aclaris Therapeutics' Non-Current Deffered Revenue fell 17.42% to $17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year decrease of 17.42%. This contributed to the annual value of $20.0 million for FY2024, which is N/A change from last year.
- According to the latest figures from Q3 2025, Aclaris Therapeutics' Non-Current Deffered Revenue is $17.5 million, which was down 3.99% from $18.2 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Non-Current Deffered Revenue registered a high of $21.2 million during Q3 2024, and its lowest value of $17.5 million during Q3 2025.
- Over the past 2 years, Aclaris Therapeutics' median Non-Current Deffered Revenue value was $19.2 million (recorded in 2025), while the average stood at $19.2 million.
- Data for Aclaris Therapeutics' Non-Current Deffered Revenue shows a maximum YoY dropped of 17.42% (in 2025) over the last 5 years.
- Aclaris Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $20.0 million in 2024, then dropped by 17.42% to $17.5 million in 2025.
- Its last three reported values are $17.5 million in Q3 2025, $18.2 million for Q2 2025, and $19.2 million during Q1 2025.